Moderna says its vaccine candidate has ‘potential’ to confer longer-term immunity

Moderna Inc. said late Thursday that its COVID-19 vaccine candidate has potential to confer longer-term immunity, and that it expects to have 20 million doses of the trial vaccine at hand in the U.S. this year. Moderna said that according to a National Institute of Allergy and Infectious Diseases study, participants in an earlier trial stage of the

Moderna high level of efficacy retained over 119 days

A medical expert has certified that the anti-Covid drug produced by Moderna had high levels of efficacy. “mRNA-1273 produced high levels of binding and neutralizing antibodies that declined slightly over time, as expected, but they remained elevated in all participants three months after the booster vaccination”, said Dr Alicia T. Widge M.D. of Vaccine

›‹

Moderna says its vaccine candidate has ‘potential’ to confer longer-term immunity

Moderna high level of efficacy retained over 119 days

Galleries and videos